TP53 and neoplasm: The panel of three anti-tumor-associated antibodies, anti-G-protein alpha subunit Gs-α (GNAS), anti-TP53, and anti-nucleophosmin 1 (NMP1), could identify 51% of ovarian cancer patients negative for CA125 [158].